摘要
目的 探讨长春瑞宾 (NVB)联合顺铂 (PDD)治疗非小细胞肺癌患者影响疗效、预后的因素。方法 分别选择临床病理因素 ,应用Logistic回归及Cox比例风险模型对影响疗效、预后的因素进行分析。结果 全组总有效率 (RR)为 30 .2 % (6 2 / 2 0 5 ) ,其中初治为 32 .0 % (4 8/ 1 5 0 ) ,复治为 2 6 .5 % (1 4 / 5 5 ) ,中位生存期 8.3个月 ,1年生存率为 37.81 % ,2年生存率为 1 5 .4 4 % ,3年生存率为 5 .39%。多因素分析显示 ,女性、肺鳞癌及治疗前一般状况较好者有较好的疗效 (P <0 .0 5 ) ;治疗前体重丢失情况与完成治疗的周期数 (P <0 .0 0 0 5 )为影响预后因素 ,肺腺癌患者在本组获得较长生存期。结论 NVB联合顺铂是治疗非小细胞肺癌较好的方案 ,影响疗效重要因素为性别、病理类型及一般状况。本组影响预后因素为治疗前体重丢失情况、完成治疗的周期数 ,肺腺癌在本组获得较长生存期。
Objective To analyze the effect, prognosis and related factors of Vinorelbine and Cisplatin combined chemotherapy in the treatment of non small cell lung cancer.Methods 205 cases who received Vinorelbine and Cisplatin combined chemotherapy were enrolled into the study.Logistic regression and Cox proportional hazard model were used to perform multivariable analysis with the clinic factors which might affect the effect and prognosis.Results A total response rate (CR+PR) was observed in 30.2%(62/205),initial treatment response and retreatment response was observed in 32%(48/150) and 26.5%(14/55).The median survival time was 8 months.Survival at one year, two year and three year represented 37.81%,15.44% and 5.39% respectively.The multivariate analysis showed female( P =0.003),squamous carcinoma and better performance status( P <0.05)were effect influencing factors.Weight loss,number of treating courses were the prognosis influencing factors ( P <0.0005).Adenocarcinoma had better long term survival.Conclusions Vinorelbine plus Cisplatin combination chemotherapy is a better regimen in the treatment of non small cell lung cancer.The main factors that influence the efficacy were gender,pathological type,and performance status;while pathological type,performance status,weight loss,and number of treating courses were prognosis influencing factors.Patients with adenocarcinoma has better long term survival rate.
出处
《北京医学》
CAS
北大核心
2004年第3期176-179,共4页
Beijing Medical Journal
